相关实验视频

Updated: Sep 16, 2025

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

关氨酸核酸结合的Rac特异性竞争性抑制剂减少了三阴性乳腺癌的转移

Florian Dilasser¹, Lindsay Rose¹, Agnès Quemener²

¹Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes F-44000, France.

Cell reports. Medicine

|July 9, 2025

概括

研究人员确定了A41,一种新型RAC1抑制剂,可以阻止癌细胞迁移和转移. 这种分子显示出作为侵袭性癌症的治疗剂的前景,在临床前模型中提高了生存率.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

失调的RAC1活性与癌症的发展,转移和患者预后不佳有关.
准RAC1为癌症治疗提供了一个潜在的策略.

研究的目的:

发现和描述RAC1.1的新型抑制剂.
在临床前癌症模型中评估已识别的RAC1抑制剂A41的治疗潜力.

主要方法:

在子选中识别RAC1抑制剂.
生物化学测试以表征抑制剂的作用机制.
在体外评估RAC1依赖的细胞功能 (粘附,迁移).
在三阴性乳腺癌的小鼠模型中的体内研究.

主要成果:

一种新的RAC1抑制剂A41被确定具有独特的作用机制.
A41作为可逆抑制剂,与关氨酸核酸与RAC蛋白结合竞争.
A41有效抑制RAC1活动,细胞粘附和迁移.
在临床前模型中,慢性A41的使用显示出抗转移效应和改善生存率.

结论:

A41是一种强效和特定的RAC1抑制剂,具有抗转移性质.
A41代表了对侵袭性癌症的有希望的治疗候选者.
用A41准RAC1可能为癌症治疗提供一个新的策略.

关键词:

在RAC1中,RAC1是指RAC1.发现药物的发现.侵袭性癌症是一种侵袭性癌症.三重阴性乳腺癌是什么

更多相关视频

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior

Published on: June 12, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...